Venkatraghavan Lashmi, Tan Tze Ping, Mehta Jigesh, Arekapudi Anil, Govindarajulu Arun, Siu Eric
Department of Anesthesia, Toronto Western Hospital, University Health Network, Toronto, Ontario, M5T 2S8, Canada.
F1000Res. 2015 May 22;4:123. doi: 10.12688/f1000research.6474.1. eCollection 2015.
Neutrophil:lymphocyte ratio (NLR) is an emerging biomarker that is used to predict postoperative mortality and morbidity in cardiac and cancer surgeries. The association of this biomarker with systemic illness and its usefulness in risk assessment of preoperative patients has not been fully elucidated.
To determine the prevalence of elevated NLR in preoperative patients and to examine the relationship between elevated NLR and the presence of systemic illnesses as well as anaesthesia risk indices such as American Society of Anesthesia (ASA) and the revised cardiac risk index (RCRI) scores.
Cross-sectional study Setting: Anaesthesia pre-admission clinic, Toronto Western Hospital, Toronto, Canada Patients: We evaluated 1117 pre-operative patients seen at an anesthesia preadmission clinic.
NLR was elevated (>3.3) in 26.6% of target population. In multivariate analysis, congestive cardiac failure, diabetes mellitus and malignancy were independent risk factors predicting raised NLR. After regression analysis, a relationship between NLR and ASA score (Odds Ratio 1.78; 95% CI: 1.42-2.24) and revised cardiac risk index (RCRI, odds ratio 1.33; 95% CI: 1.09-1.64, p-value: 0.0063) was observed.
NLR was elevated (> 3.3) in 26.6% of patients. Congestive cardiac failure and malignancy were two constant predictors of elevated NLR at >3.3 and > 4.5. There was a strong association between NLR and anesthesia risk scoring tools of ASA and RCRI.
中性粒细胞与淋巴细胞比值(NLR)是一种新兴的生物标志物,用于预测心脏手术和癌症手术的术后死亡率和发病率。这种生物标志物与全身性疾病的关联及其在术前患者风险评估中的作用尚未完全阐明。
确定术前患者中NLR升高的患病率,并研究NLR升高与全身性疾病的存在以及麻醉风险指数(如美国麻醉医师协会(ASA)和修订的心脏风险指数(RCRI)评分)之间的关系。
横断面研究
加拿大多伦多市多伦多西部医院麻醉预入院诊所
我们评估了在麻醉预入院诊所就诊的1117例术前患者。
目标人群中26.6%的患者NLR升高(>3.3)。在多变量分析中,充血性心力衰竭、糖尿病和恶性肿瘤是预测NLR升高的独立危险因素。回归分析后,观察到NLR与ASA评分(优势比1.78;95%可信区间:1.42 - 2.24)和修订的心脏风险指数(RCRI,优势比1.33;95%可信区间:1.09 - 1.64,p值:0.0063)之间存在关联。
26.6%的患者NLR升高(>3.3)。充血性心力衰竭和恶性肿瘤是NLR>3.3和>4.5升高的两个持续预测因素。NLR与ASA和RCRI的麻醉风险评分工具之间存在密切关联。